STUDY GOALS AND OBJECTIVES
BCC Research’s goal for this study is to provide an in-depth analysis of the sequencing industry, an important industry in life sciences with enormous market potential. The approach for analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key applications (e.g., research, applied, services, sample prep, informatics) where sequencing will have market share by 2018.
BCC Research examines the markets for sequencing products and services for the years 2012, 2013 and 2018.
Special emphasis is placed on the global next-generation sequencing (NGS) diagnostic markets, which are characterized and quantified by disease indication, test complexity, test purpose and geography.
Sequencing market segments that provide exciting growth opportunities include benchtop NGS sequencing instruments and consumables; clinical diagnostics (e.g., cancer, rare genetic diseases and prenatal screening); sequencing software; and consumer sequencing services.
The report provides a comprehensive discussion of sequencing technologies, market applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for accessing sequencing industry opportunities.
REASONS FOR DOING THE STUDY
The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome.
The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies).
Beginning in 2005, the launch of next-generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests.
As a result, opportunities for sequencing products and services are emerging in diverse applications ranging, for example, from clinical diagnostics to direct to consumer genetic testing markets.
Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. Several molecular genetic tests that have been successful on non-NGS formats will run on NGS platforms in the future.
At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential.
In direct to consumer genetic testing market, there is an emerging trend to move to sequencing of specific genome regions. Compared with microarrays, sequencing provides more comprehensive information to the consumer. Recent product introductions by Full Genomes Corporation and Family Tree DNA using NGS to sequence the full Y chromosome are examples of this trend.
These technical and market factors are driving this market so that it is now timely to examine the sequencing markets.
This report fills a gap in market research as it covers the three main sequencing platforms: Sanger sequencing, NGS and 3GS.
The report provides a roadmap for understanding where sequencing is likely to be used in the life sciences during the next five years. As such, it is a useful guide for strategic and business planning, as well as for learning about the impact new sequencing technologies will have in the various market segments.
This market report will be useful to many companies involved in the direct to consumer, informatics, clinical, genetic testing and sequencing industries. It will be particularly valuable for companies in such industries as life science research tools, NGS instruments, molecular diagnostics, informatics, clinical laboratories, pharmaceutical, biotechnology, microfluidics, lab-on-a-chip and sample preparation.
SCOPE AND FORMAT
The scope of the report includes sequencing technologies, applications, industries, initiatives, markets, patents and companies. The markets for sequencing products and services are given for the years 2012, 2013 and 2018.
This report reviews the main sequencing platforms, and explains why genetic variation is important for many markets, including clinical testing. It then discusses some of the top research initiatives that are contributing to NGS applications. Market driving forces are also discussed.
The report covers the sequencing markets by workflow, including sample preparation products; sequencing instruments & consumables; informatics; and sequencing services. It includes the sequencing instrument market by platform: Sanger, NGS and 3GS and by instrument class: low throughput, high-throughput, benchtop, and handheld.
The report covers the markets for the main sequencing end use applications, including research (R&D, drug discovery & development, biotech); clinical; consumer; and applied (forensics, microbial genomics, agricultural genomics).
A key part of the report covers NGS clinical markets in depth, including by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, common diseases, and pre- and post-natal screening.
Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world.
Market data covers the years 2012, 2013 and 2018.
Industry sectors analyzed in this report include NGS instruments (including market share data for the main instrument companies); NGS target enrichment; 3GS; direct to consumer genetic testing; single cell genomics; NGS-based proteomics; informatics; information technology; clinical laboratory; and the prenatal diagnostics (including market shares for the leading NGS companies).
More than 142 companies in the sequencing industry are profiled in this report.
BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2011 through 2013, including key alliance trends.
Both primary and secondary research methodologies were used in preparing this study. BCC Research examined each of the key end-user market segments that will be commercially important during the next five years.
Based on this analysis, the current and future applications of sequencing technologies are evaluated in each of the major market segments and sales revenues are forecast for 2013 through 2018.
Based on analysis of both secondary and primary market sources, as well as the key trends in the industry, the report provides the current and projected market size for the various sequencing market segments for the years 2012, 2013 and 2018.
BCC Research performed both primary and secondary research for this report. Primary sources included key industry companies and leading research institutions. In addition, data were compiled from secondary sources, including company websites and industry, trade and government publications.
John Bergin is the author of previous BCC biotechnology reports titled Next Generation Sequencing: Emerging Clinical Applications and Global Markets; Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Applications; Biologic Imaging Reagents: Technologies and Global Markets; and Synthetic Biology: Emerging Global Markets.
Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds a BS degree in Chemistry, an MS degree in Biotechnology and a Masters of Business Administration.
BCC RESEARCH ONLINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
- Examine the complete BCC Research catalog of market research reports and place direct orders.
- Read announcements of recently published reports.
- Register for its well-known conferences.
- Request additional information on any BCC Research product.
- Take advantage of special offers.
The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
Download Report Overview